Trump to Speak at Davos Forum as Rare Earth Stocks Surge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Source: CNBC
- Rare Earth Mining Surge: In 2026, Critical Metals stock soared by 147%, U.S. Antimony rose by 85%, Energy Fuels increased by 62%, USA Rare Earth climbed by 61%, and MP Materials grew by 35%, indicating strong investment potential and market demand for rare earth resources.
- Johnson & Johnson Earnings Outlook: Johnson & Johnson (JNJ) started the year up 5%, with a 12% increase over the last three months and a 33% rise over six months, despite a slight dip on Tuesday, reflecting robust market performance and investor confidence.
- Charles Schwab Earnings Preview: Charles Schwab (SCHW) is set to report earnings on Wednesday, currently just 3% off its all-time high of $104.98 reached on January 16, with a 32% increase over the past 12 months, showcasing sustained growth momentum.
- Consumer Spending Trends Analysis: Despite the consumer discretionary sector's poor performance, JPMorgan analyst Matthew Boss noted robust spending among American consumers, particularly among low and high-income groups, indicating a trend of selective spending that could impact future retail performance.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 218.50 USD with a low forecast of 190.00 USD and a high forecast of 240.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 221.490
Low
190.00
Averages
218.50
High
240.00
Current: 221.490
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
